The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.
May 19th 2024
Atopic dermatitis (AD) in visible areas significantly impacts the romantic relationships, occupations, and sexual health of French female adult patients, according to a new study.
Dr Elaine Siegfried on Preventive Strategies to Reduce Comorbidity Risk in Atopic Dermatitis
July 2nd 2022Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, addresses the comorbidity profile associated with atopic dermatitis and the utility of disease-modifying drugs to reduce risk of comorbid conditions.
Watch
Dr Robert Sidbury on Promoting Therapeutic Adherence in Pediatric Atopic Dermatitis
June 25th 2022Robert Sidbury, MD, MPH, Chief, Division of Dermatology, Seattle Children's Hospital, speaks on strategies that clinicians can employ to promote adherence of topical and oral medications in pediatric patients with atopic dermatitis.
Watch
Study Finds Environmental, Lifestyle Risk Factors of Atopic Dermatitis in Preschool Children
June 24th 2022Several environmental and lifestyle factors were associated with significant risk of atopic dermatitis development in preschool children of Shenzhen, China, including the presence of mold in the child’s room, living in a villa/townhouse, and using composite wood floors.
Read More
Dr Elaine Siegfried Addresses Patient-Centered Therapeutic Management for Atopic Dermatitis
June 16th 2022Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, discusses therapeutic management considerations for dermatologists in consulting with diverse patients with atopic dermatitis.
Watch
FDA Widens Use of Dupilumab to Children With AD as Young as 6 Months
June 9th 2022The FDA this week expanded the use of dupilumab for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD) whose disease is not controlled with topical prescription therapies or when those treatments can't be used.
Read More
Dupilumab Efficacy in Asthma, AD, EoE, and CRSwNP Not Affected By Eosinophil Count
June 8th 2022Dupilumab-induced increases in mean eosinophil counts were shown to wane over time in patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and atopic dermatitis (AD), with incidence of eosinophilia not shown to reduce efficacy of the biologic.
Read More
Dr Robert Sidbury Reviews Novel Topical, Systemic Therapies for Pediatric Atopic Dermatitis
June 3rd 2022Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, provides an overview of recent approvals and indications under consideration for the treatment of pediatric atopic dermatitis.
Watch
Food Sensitization in Early-Onset AD Linked With Later Allergic Respiratory Diseases
May 31st 2022Pediatric patients with early-onset atopic dermatitis (AD) who reported incidence of food sensitization were associated with later allergic respiratory diseases, in which persistence of AD was linked with multiple food allergies.
Read More
Dr Elaine Siegfried Discusses Skin Color, Socioeconomic Implications of Atopic Dermatitis Management
May 19th 2022Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, explains the impact of socioeconomic status on the management of atopic dermatitis in the clinical setting.
Watch
Dupilumab Clinically Effective Long Term for Moderate to Severe Pediatric Atopic Dermatitis
May 17th 2022Findings of the 52-week phase 3 LIBERTY AD PED-OLE trial showed dupilumab to have an adequate safety profile and incremental clinical benefit with continued use among pediatric patients with moderate to severe atopic dermatitis.
Read More
Robert Sidbury, MD, MPH, chief, division of dermatology, Seattle Children's Hospital, discussed the emergence of effective therapies for the management of atopic dermatitis and how dermatologists and other providers involved in patient care can better promote earlier use of these treatments.
Watch
Study Shows Caregivers Prefer Dermatology Specialists Over PCPs for Pediatric Atopic Dermatitis
May 10th 2022Dermatology specialists were cited by diverse caregivers of children with atopic dermatitis (AD) to provide enhanced care delivery and improved AD disease control compared with primary care providers.
Read More
Dr Elaine Siegfried on Safety Considerations for JAK Inhibitors in Pediatric Atopic Dermatitis
May 6th 2022Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, speaks on safety considerations for the use of Janus kinase (JAK) inhibitors in pediatric patients with atopic dermatitis.
Watch
High Disability Burden of Atopic Dermatitis Linked With Socioeconomic Status
May 4th 2022Atopic dermatitis was associated with the greatest burden of disease compared with 2 other types of dermatitis, in which high incidence and disability-adjusted life-years rates corresponded with high sociodemographic index areas.
Read More
Dr Robert Sidbury on Mental Health Implications of Atopic Dermatitis
April 28th 2022Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, spoke on the mental health comorbidity risk linked with atopic dermatitis and how dermatologists can play a role in managing behavioral care needs of at-risk patients.
Watch
Dr Elaine Siegfried on Considerations for Systemic Therapy Use in Pediatric Atopic Dermatitis
April 20th 2022Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, discusses several pediatric patient populations with atopic dermatitis who are candidates for the use of systemic therapies.
Watch
Dr Elaine Siegfried Overviews Pathology, Targeted Therapy in Atopic Dermatitis
April 14th 2022Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, explains current knowledge on the pathology of atopic dermatitis and use of targeted biologic therapies.
Watch
Dr Robert Sidbury Discusses Impact of New AAD Guidelines on Atopic Dermatitis Treatment
April 8th 2022Robert Sidbury, MD, MPH, Chief, Division of Dermatology, Seattle Children's Hospital, discussed how new guidelines issued by the American Academy of Dermatology (AAD) regarding comorbidity risk in patients with atopic dermatitis will influence the condition's treatment.
Watch
Baricitinib Linked With Improved Skin Pain Severity, Positive QOL in Atopic Dermatitis
April 5th 2022Patients with atopic dermatitis who achieved rapid changes in skin pain severity with the Janus kinase inhibitor baricitinib were associated with clinically significant improvement in Dermatology Life Quality Index scores.
Read More
Ruxolitinib Cream Improves AD Across Body Regions, Shows Efficacy, Safety in Black Patients
March 31st 2022Findings of 2 abstracts presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting showed that ruxolitinib cream (Opzelura) demonstrated significant improvement vs vehicle in patients with atopic dermatitis of Black race and across anatomic regions.
Read More